The FDA approved Merck’s two doravirine-based HIV-1 medicines: Delstrigo, a once-daily fixed-dose combination tablet of doravirine, lamivudine and tenofovir disoproxil fumarate; and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.